<DOC>
	<DOCNO>NCT02171611</DOCNO>
	<brief_summary>To determine relative bioavailability 150 mg dabigatran etexilate pellet food 150 mg dabigatran etexilate powder resolve reconstitution solution , 150 mg dabigatran etexilate capsule healthy volunteer</brief_summary>
	<brief_title>Bioavailability Different Applications Dabigatran Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Dabigatran</mesh_term>
	<criteria>Healthy male female accord follow criterion : Based upon complete medical history , include physical examination , vital sign ( BP , PR ) , 12lead ECG , clinical laboratory test Age ≥18 age ≤50 year BMI ≥18.5 BMI ≤29.9 kg/m2 ( Body Mass Index ) Signed date write informed consent prior admission study accordance GCP local legislation Any finding medical examination ( include BP , PR ECG ) deviate normal clinical relevance Any evidence clinically relevant concomitant disease Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Surgery gastrointestinal tract ( except appendectomy ) Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder History relevant orthostatic hypotension , faint spell blackouts Chronic relevant acute infection History relevant allergy/hypersensitivity ( include allergy drug excipients ) Intake drug long halflife ( &gt; 24 hour ) within least one month le 10 halflives respective drug prior administration trial Use drug could reasonably influence result trial ( especially unspecific induce agent like St. John´s wort ( Hypericum perforatum ) prolong QT/QTc interval base knowledge time protocol preparation within 10 day prior administration trial Participation another trial investigational drug within two month prior administration trial Smoker ( &gt; 10 cigarette &gt; 3 cigar &gt; 3 pipes/day ) Inability refrain smoke trial day Alcohol abuse ( 60 g/day ) Drug abuse Blood donation ( 100 mL within four week prior administration trial ) Excessive physical activity ( within one week prior administration trial ) Any laboratory value outside reference range clinical relevance Inability comply dietary regimen trial site A marked baseline prolongation QT/QTc interval ( e.g . repeat demonstration QTc interval &gt; 450 m ) A history additional risk factor Torsade de Pointes ( e.g . heart failure , hypokalemia , family history Long QT Syndrome ) For female subject : Positive pregnancy test , pregnancy plan become pregnant study within 1 month study completion No adequate contraception study 1 month study completion , i.e . follow : implant , injectables , combine oral contraceptive , intrauterine device ( IUD ) , sexual abstinence least 1 month prior enrolment , vasectomised partner ( vasectomy perform least 1 year prior enrolment ) , surgical sterilisation ( include hysterectomy ) . Females , vasectomise partner , sexually abstinent surgically sterile ask use additional barrier method ( e.g . condom , diaphragm spermicide ) Lactation Intake medication , influence blood clotting , i.e . acetylsalicylic acid , oral vitamin K antagonists etc .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>